This article elaborates a method to isolate and identify porcine bone marrow mesenchymal stem cells (pBM-MSCs) and extracellular vesicles (EVs) derived from them, providing a methodological basis for the pre-clinical evaluation of transplantation efficacy of BM-MSCs and their derived EVs.
With the development of stem cell therapy in translational research and regenerative medicine, bone marrow mesenchymal stem cells (BM-MSCs), as a kind of pluripotent stem cells, are favored for their instant availability and proven safety. It has been reported that transplantation of BM-MSCs is of great benefit to repairing injured tissues in various diseases, which might be related to modulating the immune and inflammatory responses via paracrine mechanisms. Extracellular vesicles (EVs), featuring a double-layer lipid membrane structure, are considered to be the main mediators of the paracrine effects of stem cells. Recognized for their crucial roles in cell communication and epigenetic regulation, EVs have already been applied in vivo for immunotherapy. However, similar to its maternal cells, most of the studies on the efficacy of transplantation of EVs still remain at the level of small animals, which is not enough to provide essential evidence for clinical translation. Here, we use density-gradient centrifugation to isolate bone marrow cells (BMC) from porcine bone marrow at first, and get porcine BM-MSCs (pBM-MSCs) by cell culture subsequently, identified by the results of observation under the microscope, induced differentiation assay, and flow cytometry. Furthermore, we isolate EVs derived from pBM-MSCs in cell supernatant by ultracentrifugation, proved by the techniques of transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and western blotting successfully. Overall, pBM-MSCs and their derived EVs can be isolated and identified effectively by the following protocols, which might be widely used in pre-clinical studies on the transplantation efficacy of BM-MSCs and their derived EVs.
Over the past 10 years, stem cell therapy has promised great benefits for patients suffering from a variety of diseases and injuries, such as trauma, respiratory, and cardiovascular diseases. With progress in the field, bone marrow mesenchymal stem cells (BM-MSCs) are gradually being favored by people for their accessibility and few ethical disputes1, which have been considered the gold standard for clinical research despite other cell types2. Therapies based on BM-MSCs are also attractive to more and more researchers due to their unique ability to modulate immune and inflammatory responses and repair injured tissues via differentiation or paracrine mechanisms3.
Extracellular vesicles (EVs), as the International Society for Extracellular Vesicles (ISEV) endorses4, refer to the total particles with a lipid bilayer structure that are naturally released from cells. With the recent discoveries of various contents such as proteins, lipids, and genetic materials (e.g., miRNA, mRNA, DNA molecules, as well as long noncoding RNAs) in EVs from different cell types5, their crucial roles in cell communication and epigenetic regulation have been recognized6. As a novel substitute for maternal cells, EVs have been applied in immunotherapy and regenerative medicine with studies in vivo, which serve as the basis for the ongoing pre-clinical research and follow-up clinical trials7.
However, at present, most of the studies on the efficacy of transplantation of BM-MSCs and their derived EVs still remain at the level of small animals, which are not enough to provide the necessary evidence for clinical translation. Consequently, it is extremely urgent to carry out pre-clinical research on the transplantation of BM-MSCs and their derived EVs at the level of large animals such as swine.
It has been reported that MSCs are present in extremely low numbers in the bone marrow, accounting for only 0.01% to 0.001% of the total cells8. However, pre-clinical administration of BM-MSCs requires a large number of cells (≥107 per animal)9; the amount of EVs required is even greater, the median dose of which is 0.25 mg of protein per kilogram bodyweight in swine10. To achieve these large numbers, there is an urgent need for a safe and effective method to isolate and culture MSCs from porcine bone marrow to achieve their massive expansion in vitro and acquire their EVs with high protein concentration subsequently.
So far, there are various methods for isolating BM-MSCs and their derived EVs. The current methods for isolating BM-MSCs include direct planting of bone marrow cells (BMCs)11, density-gradient centrifugation, cell surface molecular label sorting, and flow cytometry screening. It has been reported that the cell surface molecular label sorting and flow cytometry screening result in a decrease in cell adhesion rate, an increase in 24 h mortality, and proliferation inhibition12, while direct culture of BMCs can result in a high number of mixed hematopoietic cells. Therefore, density-gradient centrifugation is now commonly used to obtain BM-MSCs. Current methods for isolating EVs from cell supernatants include ultracentrifugation, ultrafiltration, polymer precipitation, and size exclusion13. Compared with other methods, ultracentrifugation has the advantage of low cost, ease of use, and compatibility with large volume preparation without complicated pretreatment, which has been the "gold standard" for EV separation14. However, a large heterogeneity exists in reagents and techniques across different labs during the process3,15, which might be misleading to readers. This article explains a series of sequential steps to isolate pBM-MSCs and EVs derived from them in detail, and subsequent identification results prove that the method is feasible to obtain pBM-MSCs and their EVs for further analysis in pre-clinical research. We hope this systematic work can provide a methodological basis for researchers engaged in the pre-clinical evaluation of transplantation of pBM-MSCs and their derived EVs, so that clinical trials can be carried out as soon as possible.
Traditional bone marrow puncture point of minipigs was positioned at the iliac crest20. Although it is easy to locate, the amount of bone marrow extraction is limited21 (only about 5 mL in general), so it is difficult to meet the requirement of a large number of expansions in vitro for the transplantation in vivo. In this method, we repositioned the bone marrow puncture point to the proximal femur, and at least 20 mL of bone marrow can be extracted from this site, guaranteeing a sufficient amount of pBM-MSCs for subsequent cell culture.
The two main separating solutions used for isolating BM-MSCs by density-gradient centrifugation are Percoll and Ficoll. Percoll is composed of siliconized polyvinylpyrrolidone (PVP), which is a novel non-toxic and non-irritating density gradient centrifugal separating agent. The low diffusion constant of Percoll results in a relatively stable density gradient; therefore, satisfactory cell separation can usually be achieved within tens of minutes at low centrifugal forces (200-1000 x g). The method for isolation of pBM-MSCs using Ficoll has been reported previously21. Compared with Ficoll, Percoll has been gradually used due to its advantages of easy isopermeability, low viscosity, non-toxicity, and not causing cell aggregation, which can complement the existing methods for isolating pBM-MSCs.
In isolating and culturing pBM-MSCs, some critical steps cannot be ignored. Firstly, successful stratification of different liquid phases after density-gradient centrifugation is the key to isolating purified pBM-MSCs. BM-MSCs, as a type of bone marrow mononuclear cells (BM-MNCs), have a specific gravity similar to that of lymphocytes and monocytes, around 1.075 g/mL. The original density of Percoll is 1.130 g/mL, and to successfully obtain the cell layer containing BM-MSCs after density-gradient centrifugation, 60% isotonic density gradient separating solution (1.077 g/mL) needs to be configured in advance according to the Percoll density-concentration relationship22. Furthermore, appropriate centrifugation conditions also contribute to successful stratification. Considering the low diffusion constant of Percoll, we centrifuged the extracted bone marrow at 600 x g for 20 min at relatively low acceleration/deceleration levels (ACC = 5, DEC = 5), which achieved a good stratification effect. Secondly, appropriate planting density is also essential for cell culture. In order to acquire a sufficient number of MSCs (usually more than 107 per animal9) for subsequent transplantation, we use 175 cm2 culture flasks for cell culture. In a previous study20, the obtained BM-MNCs were usually planted into culture flasks for cultivation at a density of 5 x 105/cm2. It has been reported that after density-gradient centrifugation, 2-3 x 107 BM-MNCs can be obtained for every 5 mL of porcine bone marrow23. So, in this protocol, we recommend to plant total BM-MNCs isolated from each 20 mL porcine bone marrow into a 175 cm2 culture flask for a suitable density. Thirdly, impurities should be avoided during the isolation and culture of pBM-MSCs. When drawing the mononuclear cell phase, the pipette should not be inserted into the Percoll phase so as not to mix with the separating liquid. Moreover, after 24 h of cell planting, the culture flask should be gently shaken to reduce the adherence of red blood cells.
During the process of ultracentrifugation, high levels of protein aggregate and lipoprotein contamination through this method inevitably compromise the quantification and functional analysis of EVs14. In order to reduce contamination as much as possible in the process, 5 mm depth of liquid in the bottom should be retained every time when transferring the supernatant before the ultracentrifugation step. Meanwhile, after the first ultracentrifugation, resuspending the pellet in sterile PBS and then performing ultracentrifugation again can effectively reduce lipoprotein contamination.
Although density-gradient centrifugation and ultracentrifugation have been widely used in isolating BM-MSCs and their derived EVs, respectively, these two techniques also have their own limitations. On the one hand, the Percoll technique is lengthy and cumbersome, and yielding BM concentrate specimen via a bedside cell concentration device has been reported as an alternative method to isolate MSCs24. On the other hand, the ultracentrifugation method requires not only highly trained technicians but also expensive equipment; therefore, the combined application of two or more techniques may present a reasonable strategy for more efficient isolation of EVs25. Besides, the identification of pBM-MSCs and their derived EVs also needs improvement. For example, according to the international criteria for defining MSCs26, the expression of some positive or negative markers, such as CD73, CD34, and HLA-DR, is still missing from the identification results of BM-MSC phenotypes by flow cytometry in this study. In addition, although measures have been taken to avoid contamination during the process of isolating EVs, due to the limitations of our laboratory, we are unable to assess the purity of the EVs sample to help improve the follow-up work.
This study combines methods for the isolation of pBM-MSCs and their derived EVs sequentially, proved by the subsequent identification results systematically. In particular, we have highlighted the key operations in this series of steps, explaining some specific experimental conditions which can solve the problem of heterogeneity existing in different laboratories during this process to a certain extent. This methodic work might be widely used in pre-clinical studies on the transplantation efficacy of BM-MSCs and their derived EVs, which could provide an experimental basis with a sufficient level for clinical research.
The authors have nothing to disclose.
We thank Yang Jianzhong and Wang Xuemin for their contributions to the operation of bone marrow extraction. This work was supported by grants from CAMS Innovation Fund for Medical Sciences (CIFMS) [grant number 2016-I2M-1-009], National Natural Science Foundation of China (no: 82070307; no: 81874461).
175 cm2 cell culture flask | Thermo Fisher | 159910 | used for cell culture |
0.25% Trypsin/EDTA | Thermo Fisher | 25200056 | used to digest cells |
Adipogenic Differentiation Kit for Bone Marrow Mesenchymal Stem Cell | OriCell | GUXMX-90031 | used for adipogenic differentiation assay |
Alix Monoclonal Antibody | Thermo Fisher | MA1-83977 | used to identify extracellular vesicles(Evs) by western blotting |
APC Mouse IgG1 kappa Isotype Control | Thermo Fisher | 17-4714-42 | used to eliminate the effects of non-specific staining in flow cytometry |
CD105 (Endoglin) Monoclonal Antibody | Thermo Fisher | 17-1057-42 | used to identify pBM-MSCs by flow cytometry |
CD14 Monoclonal Antibody | Thermo Fisher | MA1-82074 | used to identify pBM-MSCs by flow cytometry |
CD29/IGTB1 Monoclonal Antibody | Thermo Fisher | MA1-19458 | used to identify pBM-MSCs by flow cytometry |
CD45 Monoclonal Antibody | Thermo Fisher | MA5-28383 | used to identify pBM-MSCs by flow cytometry |
CD63 Monoclonal Antibody | Thermo Fisher | 10628D | used to identify EVs by western blotting |
CD81 Monoclonal Antibody | Thermo Fisher | MA5-13548 | used to identify EVs by western blotting |
CD90 Monoclonal Antibody | Thermo Fisher | A15794 | used to identify pBM-MSCs by flow cytometry |
Chondrogenic Differentiation Kit for Bone Marrow Mesenchymal Stem Cell | OriCell | GUXMX-90041 | used for chondrogenic differentiation assay |
Fetal Bovine Serum | Gibco | 10099141C | used to prepare complete medium |
FITC Mouse IgG1 kappa Isotype Control | Thermo Fisher | 11-4714-42 | used to eliminate the effects of non-specific staining in flow cytometry |
Flow cytometry | BD | Accuri C6 | used for identification of cell phenotype |
FlowJo software | BD | V10 | used to analyze data from flow cytometry |
High-speed centrifuge tube (50 mL) | Beckman | 357003 | used for high-speed centrifugation |
Iscove's Modified Dulbecco's Medium | Gibco | C12440500BT | used for cell culture |
Low-temperature high-speed floor centrifuge | Avanti | J-26XPI | used for high-speed centrifugation to obtain clean conditioned medium |
Nonyl phenoxypolyethoxylethanol (NP-40) | Sigma-Aldrich | NP40S | used for the composition of RIPA lysis buffer |
Osteogenic Differentiation Kit for Bone Marrow Mesenchymal Stem Cell | OriCell | GUXMX-90021 | used for osteogenic differentiation assay |
PE Mouse IgG1 kappa Isotype Control | Thermo Fisher | 12-4714-42 | used to eliminate the effects of non-specific staining in flow cytometry |
Percoll | Cytiva | 17089102 | used to isolate porcine bone marrow mesenchymal stem cells(pBM-MSCs) |
Phenylmethanesulfonyl fluoride (PMSF) | Thermo Scientific | 36978 | used for the composition of RIPA lysis buffer |
Phosphate Buffered Saline(10x) | Beyotime | ST476 | used to prepare isotonic Percoll solution |
Phosphate Buffered Saline(1x) | Cytiva | AF29561133 | used to dilute Percoll and wash cells |
Protease inhibitor (1x) | Thermo Scientific | A32955 | used for the composition of RIPA lysis buffer |
sodium chloride | Sigma-Aldrich | S9888 | used for the composition of RIPA lysis buffer |
sodium deoxycholate | Sigma-Aldrich | D6750 | used for the composition of RIPA lysis buffer |
sodium dodecyl sulfate (SDS) | Sigma-Aldrich | L3771 | used for the composition of RIPA lysis buffer |
Transmission electron microscopy | Hitachi | HT7700 | used for electron microscopy imaging |
Tris·HCl | Sigma-Aldrich | 93363 | used for the composition of RIPA lysis buffer |
TSG101 Monoclonal Antibody | Thermo Fisher | MA1-23296 | used to identify EVs by western blotting |
Ultracentrifuge (Type 50.2 Ti Rotor) | Beckman | optima L-100XP | used for ultracentrifugation to isolate exosomes |
Ultracentrifuge tube (26.3 mL) | Beckman | 355654 | used for ultracentrifugation |
ZetaVIEW | Particle Metrix | S/N 17-310 | used for Nanoparticle Tracking Analysis |
.